article thumbnail

Episode 985: Is the IV or Nebulized Route Better When Giving Tranexamic Acid for Hemoptysis?

Pharmacy Joe

This was an open label randomized trial of 110 patients who were evenly split between IV and nebulized tranexamic acid groups. If you like this post, check outmy book A Pharmacists Guide to Inpatient Medical Emergencies: How to respond to code blue, rapid response calls, and other medical emergencies. <–

Inpatient 105
article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Although no formal contraindications are listed in AstraZeneca’s US labeling, perioperative management may require holding acalabrutinib 3 to 7 days before and after surgery to minimize bleeding risk. Hepatotoxicity and drug-induced liver injury are additional risks that require monitoring.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

Additionally, ANDA submissions should extrapolate the RLD safety and effectiveness data for drugs with the same active ingredients, dosage forms, strengths, routes, and labeling. In the 505(j) ANDA approval pathway, on the other hand, submissions can be multisource generic drugs; however, this pathway requires bioequivalence to the RLD.

article thumbnail

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

There are too many drug approvals, label updates, and new data published for even the most skilled and experienced oncology pharmacist to keep up with, let alone those still building their baseline knowledge. Oncology pharmacy practice changes at a rapid pace. Fifteen years ago, pharmacists could learn oncology on the job.

article thumbnail

Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike

Pharmacy Times

Christina Madison and Hillary Blackburn Pharmacy Focus Episode 44: Psychosocial Outcomes in Patients with IBD Pharmacy Focus Episode 45: Pharmacy in Pop Culture with Let's Pharmonize Pharmacy Focus Episode 46: Pharmacy in Pop Culture with Let's Pharmonize- Part 2 Pharmacy Focus Episode 47: How to Counsel Patients on Allergic Rhinitis Pharmacy (..)

article thumbnail

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Pharmacy Times

Its efficacy was evaluated in the 2 multicenter, single-arm open-label phase 2 clinical trials TRUST-I (NCT04395677) 3 and TRUST-II (NCT04919811). Taletrectinib is an oral, potent, central nervous system (CNS)–active, selective, next generation ROS1 inhibitor approved for the treatment of adults with advanced ROS1+ NSCLC.

article thumbnail

Episode 977: The Problem with Milrinone in CRRT

Pharmacy Joe

Milrinone labeling suggests a renal dose adjustment for patients with creatinine clearance between 10 and 50 mL/min but has no recommendations or data available for patients with ESRD or who are receiving CRRT. To access my free download area with 20 different resources to help you in your practice, go to pharmacyjoe.com/free.